Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies Inc (SINT) delivers cutting-edge advanced ceramics solutions for critical biomedical and industrial applications through its silicon nitride expertise. This news hub provides investors and industry professionals with essential updates on the company’s material science innovations, regulatory milestones, and market developments.
Access real-time announcements covering earnings reports, product launches, strategic partnerships, and research breakthroughs in antimicrobial ceramics technology. Our curated collection simplifies tracking SINTX’s progress in spinal implant advancements, industrial material innovations, and antipathogenic surface solutions.
Key updates across three focus areas: Medical Device Developments (FDA-cleared implants, clinical trial results), Technical Ceramics Innovation (3D printing materials, industrial components), and Corporate Strategy (partnerships, financial performance). Bookmark this page for streamlined monitoring of SINTX’s role in advancing ceramics technology across healthcare and manufacturing sectors.
SINTX Technologies has provided a Q3 business update revealing revenues of $0.1 million for the quarter and $0.5 million for the year-to-date. Despite challenges from COVID-19, the company managed to avoid layoffs and even hired new staff. A significant reduction in losses was noted, with losses dropping from $0.68 per share in Q3 2019 to $0.11 per share in Q3 2020. The company is exploring new opportunities in medical and non-medical markets, including antipathogenic silicon nitride applications and aerospace components, following its AS9100D certification.
SINTX Technologies has entered a joint development agreement with Iwatani Corporation of America to integrate SINTX AP2 silicon nitride powder into polymer materials. This collaboration aims to create antimicrobial surfaces for IT devices, potentially reducing the spread of respiratory diseases like SARS-CoV-2 and Influenza A. The development leverages promising data showing silicon nitride's effectiveness against viruses. Both companies plan to fund product development in both the U.S. and Japan. SINTX emphasizes this partnership as a significant step towards new product offerings and revenue generation.
SINTX Technologies has achieved AS9100D certification for its Quality Management System, allowing the company to supply components to the aviation, space, and defense markets. Certified by the British Standards Institute on October 28, 2020, SINTX's compliance with AS9100D enables listing in the OASIS database, used by major aerospace companies like Boeing and Lockheed Martin for supplier selection. In addition to AS9100D, SINTX maintains ISO 9001:2015 and ISO 13485:2016 certifications, underscoring its commitment to stringent quality standards across sectors.
SINTX Technologies has secured US Patent 10,806,831, which covers antibacterial biomedical implants utilizing silicon nitride. This patent expands the company's capability to enhance the antibacterial properties of various implants, including those made from PEEK and titanium. The company plans to launch a composite product in early 2021. SINTX's silicon nitride can also be used in face masks to neutralize pathogens. This patent strengthens SINTX's intellectual property position in the biomedical sector.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced progress in the development of a "catch-and-kill" mask designed to inactivate respiratory viruses, including SARS-CoV-2. The company has successfully embedded silicon nitride particles into fabric, marking a significant step in mask production. The next phases involve fabric testing and manufacturing scale-up. Dr. Bal, CEO of SINTX, emphasizes the mask's potential market beyond COVID-19, addressing air quality concerns in densely populated areas. Collaboration with O2TODAY aims to bring this innovative mask to market, enhancing public health safety.
SINTX Technologies has appointed Michael Marcroft as Vice President of Business Development, focusing on the medical device sector. With nearly 20 years of experience from companies like 3M and Medtronic, Marcroft aims to leverage the potential of silicon nitride, a key biomaterial. Dr. Sonny Bal, CEO, expressed confidence that Marcroft's expertise will open new market opportunities. SINTX, specializing in silicon nitride ceramics, is positioned for growth in diverse medical applications, including arthroplasty and dental implants.
SINTX Technologies (NASDAQ: SINT) announced the filing of a universal shelf registration statement on Form S-3 with the SEC. The filing allows SINTX to access capital markets in the future up to $75 million, enhancing financial flexibility for growth opportunities. While there are no immediate plans to issue securities, this move is considered prudent for standard corporate governance. The registration statement has not yet become effective, and sales will only occur following its effectiveness.
SINTX Technologies (NASDAQ: SINT) announced new studies confirming that its silicon nitride inactivates SARS-CoV-2 and Influenza A. Conducted at George Mason University, the findings highlight a strong, dose-dependent antiviral effect after just one minute of exposure. The research aims to advance the development of consumer masks incorporating silicon nitride. SINTX is exploring additional applications in various industries, including automotive and biomedicine, while collaborating with O2TODAY on mask production. Notably, silicon nitride is non-toxic to mammalian cells.
SINTX Technologies, an OEM ceramics company specializing in silicon nitride, has announced a business update conference call on August 19th, 2020, at 3:00 p.m. Eastern Time. Interested parties can join the call by dialing 877-524-8416 or 412-902-1028 internationally. Questions for the call can be submitted via email to IR@SINTX.com until 9:00 a.m. Eastern Time on August 17. A digital replay of the call will be available on the SINTX website.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the closing of a registered direct offering of 3,415,000 shares at $2.40 per share, raising gross proceeds of $8.2 million. The shares were offered under a previously filed shelf registration statement. Maxim Group LLC served as the sole placement agent. The proceeds will be allocated for general working capital and corporate purposes. SINTX specializes in the production of silicon nitride ceramics for medical applications, with its manufacturing facility FDA registered and ISO certified.
